text size: T | T
Back to Snapshot
Company Description

Contact Info

4452 Beltway Drive

Addison, TX 75001

United States

Phone: 214-905-5145

Fax: 214-905-5130

ULURU Inc., a specialty pharmaceutical company, develops and commercializes a range of wound care and mucoadhesive film products based on patented Nanoflex and OraDisc technologies. Products The company has used its drug delivery technology platforms to develop the following products and product candidates: Altrazeal Altrazeal Transforming Powder Dressing is indicated for exuding wounds, such as partial thickness burns, donor sites, abrasions, non-healing surgical wounds, trauma and chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers. The powder fills and seals the wound to provide an optimal moist wound healing environment. The wound exudate is controlled through the high moisture vapor transpiration rate of the material. In 2010, the company entered into a licensing and supply agreement with Jiangxi Aiqilin Pharmaceuticals Group Company, a corporation in China (Aiqilin), for the development and commercialization of Altrazeal in China, including Hong Kong, Macau, and Taiwan. Aiqilin also has been granted certain manufacturing rights. The agreement covers Altrazeal, Altrazeal Silver, and Altrazeal Collagen. Aphthasol (Amlexanox 5% Paste) Aphthasol, amlexanox 5% paste, is a drug approved by the United States Food and Drug Administration (FDA) for the treatment of canker sores. Aphthasol accelerates the healing of canker sores which results in a statistically significant reduction in the level of pain a patient experiences over the duration of the ulcer episode. OraDisc A The company has developed an adhesive film product that is bioerodible. This technology, known as OraDisc, comprises a multi-layered film having an adhesive layer, an optional pre-formed film layer, and a coated backing layer. OraDisc A was developed as a drug delivery system to treat canker sores using the same active ingredient (amlexanox) that is used in Aphthasol paste. OraDisc A was approved by the FDA in 2004. OraDisc B A second mucoadhesive disc product also has been developed for the treatment and management of oral pain. This product contains 15 milligrams of benzocaine which is the maximum allowable strength that falls under the classification of an OTC monograph product in the United States. The product has been optimized and is ready for commercial scale-up. In 2012, the company executed a license and supply agreement with ORADISC GmbH (Ora-D) to market worldwide all applications of its OraDisc erodible film technology for dental applications, including but not limited to benzocaine (OraDisc B). Strategy The company’s strategy is twofold: establish a market leadership position in wound management by developing and commercializing a customer focused portfolio of innovative wound care products based on Nanoflex technology to treat the various phases of wound healing; and develop oral mucoadhesive film technology (OraDisc) for systemic drug delivery and for delivery of actives to the oral cavity. Research and Development During the year ended December 31, 2015, the company expended approximately $764,000 for research and development. Regulations The company is subject to extensive regulation by the federal government, principally by the United States Food and Drug Administration (FDA), and to a lesser extent, by other federal and state agencies, as well as comparable agencies in foreign countries where registration of products will be pursued. The Federal Food, Drug and Cosmetic Act and other federal, state and foreign statues and regulations govern the testing, manufacturing, safety, labeling, storage, shipping, and record keeping of the company’s products. Intellectual Property Patents: With regards to its Nanoflex technology, three patents have issued in the U.S. and multiple patents have been issued in international countries. There are also four PCT patent applications that have been filed and nine patent applications filed in nine international countries. The granted patents and patent applications have various potential applications, such as wound management, burn care, dermal fillers, artificial discs and tissue scaffold. The company has one U.S. patent and has filed one PCT patent application for its OraDisc technology. Competition Majority of the company’s competitors in the wound care market include Smith & Nephew plc; Systagenix Wound Management Limited; ConvaTec Inc.; 3M Company; and Molnlycke Health Care.

 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

ULUR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ULUR.
View Industry Companies
 

Industry Analysis

ULUR

Industry Average

Valuation ULUR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 6.0x
Price/Book 1.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 5.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact ULURU INC, please visit www.uluruinc.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.